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Red, is not only a color; it’s a branch of biotechnology which helps mankind fight 
either infectious or inherited diseases.  We are already in the 21st century, and yet we 
still witness multiple diseases. Some of them are even endemic, which makes it worse. 
Red Biotechnology has been used since man discovered MOs and distinguished 
infectious agents. Since then we have been trying to find cures for different disease, 
biopharmaceuticals were being used effectively since the discovery of Penicillin by 
Alexander Fleming in 1928, and recombinant human insulin (rHI, trade name Humu-
lin), which was developed by Genentech and marketed by Eli Lily in 1982. 
Since then, MOs have been evolving and we are running out of anti-biotics, as they 
grow resistant to it a day after day. Biotechnology is developing as well, but obviously 
not as fast. Techniques on its own is very expensive; trials take a long time as well. The 
question is, would biotechnology be able to meet the needs of a biological system? 
Would we be able some day to fight back MOs with their weapon?  
Here, we’ll try to review some of the latest techniques in the field, which makes us 
understand how far we’ve come, and realize our capabilities and challenges on top. 
Transgenics is considered a solution for many dilemmas we have nowadays. We 
believe it’s a promising solution, nothing is much better than using a bioreactor which 
could be an animal, plant or even a bacterium to produce a medicine which is desper-
ately needed. 
Nanomedicine ranges from the medical applications of nanomaterials and biologi-
cal devices, to nanoelectronic biosensors, and even possible future applications of mo-
lecular nanotechnology such as biological machines. Current problems for nanomedi-
cine involve understanding the issues related to toxicity and environmental im-
pact of nanoscale materials. 
3D BioPrinting, the process of using bioink composed of tissue or human cells, has 
come a long way over the last decade. The goal of developing functioning whole organs, 
such as kidneys, livers or hearts, is becoming more and more of a reality. 
Host Cell Proteins (HCPs) are process-related impurities, expressed by the host cell 
used for production of biopharmaceutical proteins. During the purification process, the 
majority of HCPs are removed (>99%), but small HCP amounts remain in the distrib-
uted products, such as monoclonal antibodies (mAbs), antibody-drug-conju-
gates(ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuti-
cals. 
Antibody-drug conjugates or ADCs are an important class of highly potent bio-
pharmaceutical drugs. ADCs are a mixed complex of Anti-body and cytotoxic drug, 





In Conclusion, we could say that our future is safe with such techniques, but our 
present is still vague. All the technology we have today, are not applicable due to their 
great cost; but science has not limit. We might be able to use it tomorrow on daily basis 
in every laboratory or hospital. What we are not sure about is the revelation and chal-
lenges, the biological system is holding for us. That’s why we need to be one step ahead 
all the way. 
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Annotation. The goal of the project is to design a program based on machine learning 
algorithms, performing analysis of a one-dimensional ECG signal and reporting a particular 
pathology. 
 
Основной проблемой ЭКГ-метода диагностики сердечно-сосудистых заболе-
ваний является то, что традиционные методы анализа достаточно часто обладают 
малой достоверностью. Некоторые серьезные заболевания сердца отражаются на 
ЭКГ лишь малозаметными изменениями амплитуды или формы пиков. В таких 
случаях точность диагноза зависит почти полностью от опыта и классификации 
врача. Для исключения «человеческого фактора» процесс необходимо автомати-
зировать и найти метод, способный распознавать любые характерные для опре-
деленного заболевания изменения. В данном проекте рассматривается вариант 
решения этой задачи с помощью использования искусственных нейронных сетей 
(ИНС) и алгоритмов машинного обучения. 
Современные ИНС могут быть использованы в качестве средства прогнози-
рования во времени, средство распознавания образов, инструмент для поиска по 
ассоциациям, модель для поиска закономерностей в массивах данных.    
Целью данного проекта будет создание ИНС, ее обучение с помощью находя-
щихся в открытом доступе отечественных и зарубежных баз данных патологиче-
ских и нормальных ЭКГ-сигналов, а также проектировка пользовательского ин-
терфейса. Для написания программы будет использоваться язык 
